.

1. PREFACTION BOOK INNOVATIVE PHARMACOLOGY 2020 some new topics – BASIC
Authors:
1) Luisetto M, independent researcher, IMA natural science branch, pharmacology
branch 29121 italy
2) Oleg yurevich Latishev IMA ACADEMY President
IMA academy natural science and pharmacology.
Introduction – discussion – conclusion
This publications is involved in some neuro-degenerative disease, oncology, some
immune disease, heart disease and other pathology (also in environmental
toxicology filed) using an evolutionary approach, environmental and sociological
approach.
Only some suggestion for new research development.
All this under an Endogenous archeological science and endogenous toxicology,
topographic new approach. (intra local micro-environmental).
Some new word are here used: lack of efficacy therapy, topography, gradients,
environment, socioeconomic status, advanced- un advanced countries, innovative
strategy, different point of view and so on.
Also success and failure of today pharmacology (see in example good
therapeutic results on some cancer or hematology disease like LMC Ph +, or
efficacy of some new cancer immunotherapy, but also other kind of condition

2. not efficacy treated whit high rate of failure or relapses like biofilm infections
related) is possible to verify that there is the need of new approach.
The same in is possible to observe current therapy textbook or pharmacology that
efficacy of solution proposed (pharmacological - Medical devices) differ from the
various condition: starting from the most efficacy solution to the less. In example
an anesthetic or curare for surgery show high efficacy vs in example other drugs
(some antimicrobials, Some anti depressant or hair loss remedies and so on).
Often to treat a condition are used association of drugs, but if in many cases it
improve efficacy due by synergy in other mask a failure of a single drug.
In oncology field many drugs are today registered even if they present low
improve in efficacy and real innovation are rare event.
Some heavy oncology condition become like chronic disease (with some new drugs
whit less mortality in last year) and this show how pharmacology success can be
obtained with some more research.
See in example also the cases of Hepatitis C, and HIV that have heavily
modified surgery approach and mortality rate.
But why some topics are not currently adequately investigated in medical field ?
(like amygdale dysfunctions, or depurative approach in some neuro-degenerative
conditions, or immune function in brain, some heart disease or biofilm
interference in some antimicrobial therapy).
Why it was introduced in last 100 years many antimicrobials molecule but less
approach to treat biofilm?
The same some similarity must be considered as well as some topographic effect
in some cancer presentation.
(see in example epidemiology of some cancer in advanced and not advanced
countries due by diet or environmental factors: the interesting example of left and
right presentation of colon cancer).
The social component of modern pharmacology is also impossible to overestimate.
Related social perception: First of all, it is expressed in that what public opinion is
emerging regarding certain methods of drug therapy.
Today in advanced countries more elderly people is present, whit high rate of
degenerative disease and high social cost (drugs, healthcare services, caregiver

3. costs) condition added to real less availability of drugs in emerging countries.
(Royalties related trade mark registered).
The new drugs registered present high initial cost due by research or by
complicated syntetic process
(MABS, molecular biology, gene therapy, CAR T).
In today research field is high needed new research topics to search new
therapeutic strategy.
An approach (in our opinion) based on evaluative science, endogenous archeological
science added to principle of endogenus toxicology make possible to think to new
therapeutic strategy.
Basic principle to be deep investigated to choose new innovative pathways in some
human disease like neuro-degenerative pathology, in oncology, toxicology, pathology
and some immune disease.
Statistics and epidemiology added to molecular biology, zoology, clinical pharmacy
and other discipline make possible a new light in this research field to
improve clinical outcomes, reduce morbidity and mortality rate, improving
pharmacokinetics and finding new therapeutic target.
Really interesting the cases of biofilm related infectious disease with high rate of
relapses and MDR.
There is the need not only of new antimicrobials but also to improve kinetics
reducing barriers to their
Actions.
Relevant results can be obtained also in social setting if some heavy disease
like neuro-degenerative and oncology or heart disease are treated with new
pharmacological strategies
Until today many neuro-degenerative disease have few efficacy drug therapy and
high social cost and in many pharmacology textbook is possible to verify that in
this condition like DA and other few drugs present

4. Low rate of global efficacy.
(in example colon cancer is more present in advanced countries diet whit high
amount of treated meat and less fibers.)
The next integral part of rethinking the strategy for the development of
pharmacology around the world must be derived from nano-technology - also
microscopic robots, artificial intelligence, genetic, molecular biology, computational
drug design, new diagnostic and monitoring techniques which will heal the body at
the cellular level and so on.
The new drugs that Having fulfilled their task, having fulfilled the function
assigned to them, they must either be excreted from the body naturally, or break
down into its constituent parts, and also freely enter the excretory system of the
human body but with less toxicity of old drugs.(see immunotherapy of cancer).
So new topics, new approach and new techniques can be the right instrument in
2020 scenario.